Trials in Glendale, Arizona
Here are the top 10 medical studies for lung cancer in Glendale, Arizona
Popular Filters
Phase 3 Trials
PD-1 Inhibitor
SC Pembrolizumab + Hyaluronidase for Non-Small Cell Lung Cancer
Recruiting2 awardsPhase 3
Phoenix, Arizona
This trial compares two methods of administering a cancer drug in adults with advanced lung cancer. It aims to see if injecting the drug under the skin is as effective as giving it directly into a vein. The drug helps the immune system attack cancer cells by blocking a specific protein.
Monoclonal Antibodies
Serplulimab + Chemotherapy for Small Cell Lung Cancer
Recruiting3 awardsPhase 3
Goodyear, Arizona
This trial is testing two different treatment combinations for patients with extensive-stage small cell lung cancer who have not received any prior treatment. One group will receive a new drug called Serplulimab along with standard chemotherapy, while the other group will receive an existing drug called Atezolizumab with the same chemotherapy. Both immunotherapy drugs aim to help the immune system fight cancer, and the chemotherapy drugs work by killing cancer cells. Atezolizumab has been shown to improve survival in small-cell lung cancer when combined with chemotherapy, changing the standard first-line therapy.
Anti-tumor antibiotic
Telisotuzumab Vedotin vs. Docetaxel for Non-Small Cell Lung Cancer
Recruiting2 awardsPhase 3
Phoenix, Arizona
This trial is testing a new drug called telisotuzumab vedotin to see if it can treat a specific type of lung cancer better than an existing drug. The study focuses on adults whose lung cancer has not responded to previous treatments. The new drug targets and kills cancer cells by attaching to a specific protein on their surface.
Chemotherapy
Adagrasib + Pembrolizumab for Lung Cancer
Recruiting1 awardPhase 2 & 3
Prescott Valley, Arizona
This trial tests two drugs, MRTX849 and pembrolizumab, in patients with advanced lung cancer who have a specific genetic mutation. MRTX849 targets the mutation to stop cancer growth, while pembrolizumab boosts the immune system to fight the cancer. The study aims to see how well these treatments work alone and together.
Tyrosine Kinase Inhibitor
Crizotinib for Non-Small Cell Lung Cancer
Recruiting2 awardsPhase 3
Phoenix, Arizona
This trial studies crizotinib for patients with stage IB-IIIA NSCLC who have had surgery and have an ALK fusion mutation. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working.
Trials With No Placebo
Anti-metabolites
Vudalimab or Pembrolizumab with Chemotherapy for Lung Cancer
Recruiting1 awardPhase 1 & 2
Glendale, Arizona
This trial aims to find the right amount of vudalimab to use alongside chemotherapy for patients with a specific type of lung cancer. The study will also compare the effectiveness and safety of vud
CAR T-cell Therapy
A2B530 CAR T Therapy for Solid Cancers
Recruiting1 awardPhase 1 & 2
Gilbert, Arizona
This trial tests A2B530, a treatment using modified immune cells from the patient, in adults with hard-to-treat cancers like colorectal, pancreatic, and lung cancer. The treatment aims to target and kill cancer cells while protecting healthy cells.
PD-1 Inhibitor
SC Pembrolizumab + Hyaluronidase for Non-Small Cell Lung Cancer
Recruiting2 awardsPhase 3
Phoenix, Arizona
This trial compares two methods of administering a cancer drug in adults with advanced lung cancer. It aims to see if injecting the drug under the skin is as effective as giving it directly into a vein. The drug helps the immune system attack cancer cells by blocking a specific protein.
Monoclonal Antibodies
SGN-BB228 for Melanoma
Recruiting1 awardPhase 1
Phoenix, Arizona
This trial is testing a new drug called SGN-BB228 to see if it can help treat difficult-to-treat cancers like melanoma and other solid tumors. The study will determine the safest amount of the drug to give and check if it works in shrinking or eliminating these tumors. The goal is to find a new treatment option for patients whose cancers are not responding to current therapies.
Monoclonal Antibodies
Serplulimab + Chemotherapy for Small Cell Lung Cancer
Recruiting3 awardsPhase 3
Goodyear, Arizona
This trial is testing two different treatment combinations for patients with extensive-stage small cell lung cancer who have not received any prior treatment. One group will receive a new drug called Serplulimab along with standard chemotherapy, while the other group will receive an existing drug called Atezolizumab with the same chemotherapy. Both immunotherapy drugs aim to help the immune system fight cancer, and the chemotherapy drugs work by killing cancer cells. Atezolizumab has been shown to improve survival in small-cell lung cancer when combined with chemotherapy, changing the standard first-line therapy.
View More Related Trials
Frequently Asked Questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.